玛仕度肽新适应症获批 阿里健康提供规范化用药与家庭场景诊后管理支持

e公司
Sep 23

近日,信达生物制药集团宣布公司产品玛仕度肽注射液(胰高血糖素[GCG] /胰高血糖素样肽-1[GLP-1] 双受体激动剂)在华获批新适应症,用于成人2型糖尿病患者的血糖控制。该药物自今年7月登陆阿里健康以来,已成为增速最快的GLP-1类产品之一。作为新特药首发平台,阿里健康持续助力药企提高创新药可及性,为用户提供覆盖健康管理全周期的普惠解决方案。中国是全球2型糖尿病患者人数最多的国家,成人患者达...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10